Lantern Pharma Q3 net loss $3.2M ($0.29/shr); cash $44.9M; LP-284 IND cleared, LP-184 dosed first patient

Lantern Pharma Inc.

2023-Q3 EPS reported -$1.08

Net loss $3.2M ($0.29/shr) vs $2.3M ($0.21/shr) in Q3 2022; R&D rose to $2.2M from $0.7M due to prior-year one-time payment.
Cash, equivalents, and marketable securities $44.9M at Sep 30 vs $55.2M at Dec 31; runway into at least Q3 2025.
Received FDA IND clearance for LP-284 Phase 1 trial in refractory non-Hodgkin's lymphomas; dosed first patient in LP-184 Phase 1 solid tumor basket trial.
RADR AI platform surpassed 36B oncology datapoints; new modules for ADC design, BBB permeability prediction, and IO combination therapy.
Phase 2 Harmonic trial of LP-300 in never-smoker NSCLC expanded to additional U.S. sites and Asia; Dr. Joseph Treat named lead PI.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lantern Pharma Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 8, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-039900

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.